Group 1 - Lingkang Pharmaceutical (603669) experienced a decline of 8.01% in its stock price today, with a turnover rate of 8.01% and a trading volume of 387 million yuan [1] - The stock exhibited a volatility of 16.07% throughout the day, leading to its listing on the Shanghai Stock Exchange's watchlist [1] - Data from the Longhu list indicates that institutional investors collectively sold a net amount of 67.5 million yuan [1]

证券代码：603669 证券简称：灵康药业 公告编号：2024-072 剂型：注射剂 注册分类：化学药品 规格：1.25g（按 C₁₆H₁₆N₄O₈S 计） 受理号：CYHB2450250 上市许可持有人：海南灵康制药有限公司 灵康药业集团股份有限公司 关于子公司注射用头孢呋辛钠 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）全资子公 司海南灵康制药有限公司（以下简称"灵康制药"）近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的关于"注射用头孢呋辛钠"（以下简称 "该药品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性 评价。现将有关情况公告如下： 一、药品基本情况 （一）药物名称：注射用头孢呋辛钠 （二）药物名称：注射用头孢呋辛钠 剂型：注射剂 注册分类：化学药品 规格：1.75g（按 C₁₆H₁₆N₄O₈S 计） 地址：海南省海口国家高新技术产业开发区药谷工业园药谷二横路 16 号 生产企业：海南灵 ...

Financial Performance - Revenue for the first three quarters of 2024 reached 2.31 billion yuan, a year-on-year increase of 53.34% [1] - Net profit attributable to the parent company was -46.89 million yuan, with a reduction in loss of 51.45% [1] - Third-quarter revenue was 89.55 million yuan, a year-on-year increase of 137.26% [1] - Main pharmaceutical business grew by 48.42% year-on-year in the first three quarters [2] Strategic Initiatives - Participating in the 10th national centralized procurement for two products: Injection of Latamoxef Sodium and Injection of Esmolol Hydrochloride [2] - Entering the CMO business for the first time to maximize production capacity utilization [2] - Leveraging provincial alliance centralized procurement for core product Injection of Cefuroxime Sodium, covering 11 and 21 provinces respectively [2] - Implementing cost control measures through refined management [2] Product Portfolio - Injection of Latamoxef Sodium has a market capacity of approximately 3 billion yuan annually, with 9 qualified enterprises [2] - Injection of Huperzine A is a proprietary product with significant market potential, currently covering less than one-fifth of China [3][4] - Injection of Esmolol Hydrochloride has a market capacity of about 1.1 billion yuan, with 18 qualified enterprises [4] International Expansion - Partnering with French company Laboratoire Bailly-Creat for African and Southeast Asian markets [4] - Targeting Africa's pharmaceutical market with a population of 1.4 billion and annual drug consumption of over 10 billion USD [5] - Expanding to "Belt and Road" countries, with China having signed over 200 cooperation documents with 152 countries [5] R&D and Innovation - Obtained four new consistency evaluation approvals in 2024 [6] - Currently has 27 approved or deemed approved specifications and 8 R&D projects [6] - Transitioning from generic drugs to innovative drugs, with two new 2.2 class solid preparations initiated in 2024 [6] - R&D investment consistently exceeds 10% of revenue [7] Future Plans - Considering equity incentives and employee stock ownership plans [7] - Focusing on mergers and acquisitions to enhance product portfolio and scale [8] - Targeting innovative drugs, biological drugs, and companies with technical or policy barriers [8]

Financial Performance - The company's operating revenue for Q3 2024 reached ¥89,552,626.84, representing a year-on-year increase of 137.26%[2] - The net profit attributable to shareholders for Q3 2024 was -¥6,489,699.32, with a year-to-date net profit of -¥46,889,888.23[2] - The basic earnings per share for Q3 2024 was -¥0.01, and the diluted earnings per share was also -¥0.01[3] - The company achieved a year-to-date operating revenue increase of 53.34%, driven by enhanced product promotion and channel utilization[6] - Total operating revenue for the first three quarters of 2024 reached ¥231,030,545.43, a significant increase of 53.3% compared to ¥150,665,541.41 in the same period of 2023[19] - The company reported a net loss of ¥46,889,888.23 for the first three quarters of 2024, an improvement from a net loss of ¥96,582,500.85 in the same period of 2023[21] - Operating profit (loss) improved to -¥52,997,337.55 from -¥93,993,126.65 year-over-year[21] - Basic and diluted earnings per share improved to -¥0.07 from -¥0.13 year-over-year[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,205,651,919.73, a decrease of 25.79% compared to the end of the previous year[3] - The total assets decreased to ¥1,205,651,919.73 from ¥1,624,560,125.88, a decline of 25.7%[18] - The company’s equity attributable to shareholders decreased by 8.09% year-on-year, totaling ¥855,722,332.04[3] - The total liabilities decreased to ¥349,929,587.69 from ¥693,517,978.39, a reduction of 49.6%[18] - Current assets totaled RMB 495,170,740.50, down from RMB 881,533,254.03 in the previous period, indicating a significant reduction[16] - Non-current assets totaled RMB 710,481,179.23, down from RMB 743,026,871.85, indicating a decrease of about 4%[17] Cash Flow - The company reported a net cash flow from operating activities of -¥64,056,674.63 for the year-to-date period[3] - The net cash flow from operating activities for the first three quarters of 2024 was -64,056,674.63 RMB, compared to -21,150,724.69 RMB in the same period of 2023, indicating a decline in operational cash flow[25] - Total cash inflow from operating activities decreased to 211,980,745.20 RMB in 2024 from 260,896,973.39 RMB in 2023, reflecting a year-over-year decline of approximately 18.7%[25] - Cash outflow from operating activities was 276,037,419.83 RMB in 2024, slightly down from 282,047,698.08 RMB in 2023, showing a decrease of about 2.5%[25] - The company reported a significant reduction in cash flow from operations, impacting liquidity and operational flexibility[16] Investments and Financing - The company received government subsidies amounting to ¥14,483,829.44 year-to-date, which positively impacted its financial performance[4] - Cash inflow from investment activities was 196,544,899.48 RMB in 2024, significantly lower than 599,270,726.35 RMB in 2023, representing a decline of approximately 67.2%[25] - The net cash flow from investment activities improved to 185,104,669.99 RMB in 2024, compared to -89,657,920.92 RMB in 2023, indicating a positive turnaround[25] - Cash inflow from financing activities was 222,004,918.60 RMB in 2024, up from 118,646,944.44 RMB in 2023, marking an increase of approximately 87.2%[25] - The net cash flow from financing activities was -314,288,040.40 RMB in 2024, worsening from -4,127,640.96 RMB in 2023, indicating increased financial strain[25] Operational Changes - The company is actively seeking CMO orders to maximize production capacity and reduce costs[7] - There were no new product launches or major strategic initiatives mentioned during the earnings call, indicating a focus on financial restructuring and cost management[16] - Research and development expenses decreased to ¥14,987,666.90, down 29.5% from ¥21,226,696.58 in the previous year[19] - The company reported a significant increase in cash paid for purchasing goods and services, rising to 145,189,289.44 RMB in 2024 from 107,302,510.84 RMB in 2023, an increase of approximately 35.3%[25] - Cash paid for employee compensation decreased to 36,462,803.02 RMB in 2024 from 41,659,416.41 RMB in 2023, reflecting a decrease of about 12.0%[25]

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2024-071 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （三）根据《上海证券交易所股票上市规则》等相关规定以及《灵康药业集 团股份有限公司公开发行可转换公司债券募集说明书》（以下简称"募集说明书"） 的有关约定，公司该次发行的"灵康转债"自 2021 年 6 月 7 日起可转换为本公 司 A 股普通股股票，目前转股价格为 8.00 元/股。 1 （四）因"灵康转债"触发《灵康药业集团股份有限公司公开发行可转换公 司债券募集说明书》中约定的回售条款，公司于 2024 年 6 月 24 日至 2024 年 6 月 28 日进行了回售，回售数量为 2,048,260 张，回售资金已于 2024 年 7 月 3 日 发放。 二、可转债本次转股情况 "灵康转债"自 2024 年 7 ...

证券代码：603669 证券简称：灵康药业 公告编号：2024-069 灵康药业集团股份有限公司 关于控股股东股票质押式回购交易延期购回的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 截至公告披露日，公司控股股东灵康控股集团有限公司（以下简称"灵 康控股"）直接及间接持有公司股份 33,965.28 万股无限售流通股股票，占公司 总股本的 47.09%，灵康控股累计质押公司股票数量为 10,482.96 万股，占其持 有公司股份总数的 30.86%，占公司总股本的 14.53%。 2、本次延期购回的股份不存在用作重大资产重组业绩补偿等事项的担保或 其他保障用途等情况。 3、控股股东及其一致行动人累计质押股份情况 截至目前，灵康控股所持股份的质押风险可控，不存在引发平仓或被强 制平仓的风险。 2024 年 9 月 24 日，灵康药业集团股份有限公司（以下简称"灵康药业"或 "本公司"）接到公司控股股东灵康控股关于股票质押式回购交易延期购回的通 知，现将相关情况公告如下： 一、本次股票质押式回购交易延 ...

截至公告披露日，公司控股股东灵康控股集团有限公司（以下简称"灵 康控股"）直接及间接持有公司股份 33,965.28 万股无限售流通股股票，占公司 总股本的 47.09%，灵康控股本次解除质押股份 2,000.00 万股,占其持有公司股 份总数的 5.89%，占公司总股本的 2.77%。 2024 年 9 月 24 日，灵康药业集团股份有限公司（以下简称"灵康药业"或 "本公司"）接到公司控股股东灵康控股关于部分股份解除质押的通知，现将相 关情况公告如下： | 股东名称 | 灵康控股 | | --- | --- | | 本次解除质押股份 | 2,000.00 万股 | | 占其所持股份比例 | 5.89% | | 占公司总股本比例 | 2.77% | | 解除质押时间 | 2024 年 9 月 20 日 | | 持股数量 | 33,965.28 万股 | | 持股比例 | 47.09% | | 剩余被质押股份数量 | 10,482.96 万股 | | 剩余被质押股份数量占其所持股份比例 | 30.86% | | 剩余被质押股份数量占公司总股本比例 | 14.53% | 经与灵康控股确认，解除质押的股份暂无后续 ...

注册分类：化学药品 证券代码：603669 证券简称：灵康药业 公告编号：2024-068 灵康药业集团股份有限公司 关于子公司左卡尼汀注射液 通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）全资子公 司海南美兰史克制药有限公司（以下简称"美兰史克"）近日收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的关于"左卡尼汀注射液"（以下简 称"该药品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致 性评价。现将有关情况公告如下： 一、药品基本情况 （一）药物名称：左卡尼汀注射液 剂型：注射剂 规格：5ml：1g 受理号：CYHB2350738 上市许可持有人：海南美兰史克制药有限公司 地址：海口市南海大道 168 号海口保税区 6 号路 生产企业：海南灵康制药有限公司 地址：海南省海口国家高新技术产业开发区药谷工业园药谷二横路 16 号 药品批准文号：国药准字 H20203512 审批结论：根据《中华人民共和国药品管 ...

证券代码：603669 证券简称：灵康药业 公告编号：2024-067 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"或"灵康药业"）全资子公 司海南灵康制药有限公司（以下简称"灵康制药"）近日收到国家药品监督管理 局（以下简称"国家药监局"）核准签发的关于"注射用头孢唑肟钠"（以下简称 "该药品"）《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性 评价。现将有关情况公告如下： 一、药品基本情况 （一）药物名称：注射用头孢唑肟钠 剂型：注射剂 注册分类：化学药品 规格：0.5g（按 C₁₃H₁₃N₅O₅S₂计） 灵康药业集团股份有限公司 关于子公司注射用头孢唑肟钠 通过仿制药一致性评价的公告 注册分类：化学药品 规格：2.0g（按 C₁₃H₁₃N₅O₅S₂计） 受理号：CYHB2450194 上市许可持有人：海南灵康制药有限公司 地址：海南省海口国家高新技术产业开发区药谷工业园药谷二横路 16 号 生产企业：海南灵康制药有限公司 地址：海南省海口国家高新技术产业开发 ...

| 证券代码：603669 | 证券简称：灵康药业 | 公告编号：2024-066 | | --- | --- | --- | | 债券代码：113610 | 证券简称：灵康转债 | | 灵康药业集团股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 灵康药业集团股份有限公司（以下简称"公司"）于近日收到中信证券股份 有限公司（以下简称"中信证券"）出具的《中信证券股份有限公司关于更换灵 康药业集团股份有限公司公开发行可转换公司债券持续督导保荐代表人的函》， 具体情况如下： 2024 年 8 月 31 日 1 附：保荐代表人何康简历 何康先生，保荐代表人、非执业注册会计师、律师执业资格，硕士研究生学 历，具有 8 年以上投资银行工作经验，曾负责或参与：屹通新材、百华悦邦、华 塑科技、认养一头牛等 IPO 项目，以及开山股份非公开、灵康药业可转债、新安 股份资产重组、百隆东方非公开等再融资及重大资产重组项目。 2 中信证券作为公司公开发行可转换公司债券的保荐机构，指定向晓娟女士、 ...